Bitotech Halozyme Therapeutics ( HALO) was my "top pick" for the second quarter. The quarter has ended, so let's check out the charts to see if this was a worthwhile trade and if we should continue holding HALO. 
In this daily bar chart of HALO, below, we can see that prices have managed a move higher the past three months. Compared to the performance of the broad market averages, this recommendation has been a winner, but I am not ready to take a victory lap just yet.
Prices are currently testing the rising 50-day moving average line. The 200-day moving average line has turned positive in the past six weeks. The On-Balance-Volume (OBV) line shows a rise from early December. The trend-following Moving Average Convergence Divergence (MACD) oscillator is above the zero-line but needs renewed price strength to turn things more bullish.
In this weekly Japanese candlestick chart of HALO, below, we find a positive-looking picture. Prices are trading above the rising 40-week moving average line. The weekly OBV line shows strength the past four to five months. I do not see a top reversal pattern nor worrisome upper shadows. The MACD oscillator is bullish, but shows some recent narrowing.
In this daily Point and Figure chart of HALO, below, we can see an upside price target in the $58 area.
In this weekly Point and Figure chart of HALO, below, we can see that prices have reached an upside price target. A trade at $49.03 should refresh the uptrend and generate a new bullish price target.
Bottom line strategy: Overall, the charts and indicators of HALO remain positive. Traders could continue to hold existing longs and consider adding to longs or going long above $49. The $58 area is our price target.
